Literature DB >> 23485609

Extended-release carbidopa-levodopa in Parkinson's disease.

Olivier Rascol1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23485609     DOI： 10.1016/S1474-4422(13)70039-5

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  3 in total

Review 1.  Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.

Authors:  Sarah L Greig; Kate McKeage
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

2.  Eryptosis as a marker of Parkinson's disease.

Authors:  Etheresia Pretorius; Albe C Swanepoel; Antoinette V Buys; Natasha Vermeulen; Wiebren Duim; Douglas B Kell
Journal:  Aging (Albany NY)       Date:  2014-10       Impact factor: 5.682

Review 3.  The role and structure of the multidisciplinary team in the management of advanced Parkinson's disease with a focus on the use of levodopa-carbidopa intestinal gel.

Authors:  Stephen W Pedersen; Martin Suedmeyer; Louis W C Liu; Dirk Domagk; Alison Forbes; Lars Bergmann; Koray Onuk; Ashley Yegin; Teus van Laar
Journal:  J Multidiscip Healthc       Date:  2017-01-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.